Davies, T. W.
van Gassel, R. J. J.
van de Poll, M.
Gunst, J.
Casaer, M. P.
Christopher, K. B.
Preiser, J. C.
Hill, A.
Gundogan, K.
Reintam-Blaser, A.
Rousseau, A. F.
Hodgson, C.
Needham, D. M.
Castro, M.
Schaller, S.
McClelland, T.
Pilkington, J. J.
Sevin, C. M.
Wischmeyer, P. E.
Lee, Z. Y.
Govil, D.
Li, A.
Chapple, L.
Denehy, L.
Montejo-González, J. C.
Taylor, B.
Bear, D. E.
Pearse, R.
McNelly, A.
Prowle, J.
Puthucheary, Z. A.
Article History
Received: 25 May 2022
Accepted: 25 July 2022
First Online: 6 August 2022
Declarations
:
: The questionnaires and methodology for this study was approved by the Queen Mary Ethics of Research Committee (QMREC20.241). Informed consent was implied by completion of the survey, consistent with standard practice for survey research.
: Not applicable.
: ZP has received honoraria for consultancy and/or speaker fees from Nestle, Fresenius Kabi, Nutricia, Baxter and Faraday Pharmaceuticals, and research and educational grants from Nestle and Baxter. ARB has received honoraria for consultancy and/or speaker fees from Nestlé, Fresenius Kabi, VIPUN Medical and Nutricia, and a research grant from Fresenius Kabi. SS reports grants from Reactive Robotics GmbH (Munich, Germany), grants and non-financial support from STIMIT AG (Biel, Switzerland), Liberate Medical LLC (Crestwood USA), ESICM (Geneva, Switzerland), grants, personal fees and non-financial support from Fresenius Kabi Deutschland GmbH (Bad Homburg, Germany), personal fees from Springer Verlag GmbH (Vienna Germany) for educational purposes, non-financial support from Technical University of Munich (Munich, Germany) and from National and international societies (and their congress organisers) in the field of anesthesiology and intensive care medicine, outside the submitted work. SS held stocks in small amounts from Rhön-Klinikum AG and holds stocks in small amounts from Alphabeth Inc., Bayer AG and Siemens AG; these holdings have not affected any decisions regarding his research or this study. AH’s position is currently supported by a stipend from the Medical Faculty RWTH Aachen ‘Habilitationsstipendium.’ Within the last 36 months AH received lecture fees from Fresenius Kabi Germany and grants for investigator initiated trials from the DFG, Fresenius Kabi Germany, and Lotte & John Hecht Memorial foundation. None of the disclosed financial relationships may be perceived as inappropriately influencing AH’s contribution to this project or this manuscript. MVP received research funding from Fresenius-kabi and Nutricia Research, speakers fee from Nutricia. MVP is principal investigator of the PRECISe trial, which uses a COS for resp failure by DN. MPC receives funding from the Research Foundation Flanders (FWO) (Grant No. 1832817 N) and Onderzoeksraad, KU Leuven (Grant No. C24/17/070) and from the Private Charity Organisation ‘Help Brandwonden Kids.’ DEB has received speaker fees from Baxter Healthcare and has received research grant funding from Nutricia Ltd. All other authors declare that they have no competing interests.